Characterize the longitudinal trajectories of patients infected with SARS-CoV-2 to inform research questions and clinical care.
Vision
Understand the factors that underlie the pathobiology of COVID-19, the progression to severe illness or death, and the effectiveness of therapeutic interventions in order to provide personalized care to patients infected with SARS-CoV-2.
Mission
Improve the care of patients infected with SARS-CoV-2 by learning about COVID-19 pathobiology, likelihood of disease progression and impact of specific therapeutic interventions. We aim to provide this information to clinicians, patients and family members at the point of care.
COVID-19 Research
The research aims that inform us on how to best care for patients include:
COVID-19 Disease Trajectory
Prediction Modeling
Develop prediction models of COVID-19 severe disease and death that can be used at the point of care to inform treatment decisions, resource allocation and discussions with patients and families.
Effectiveness of Therapeutic Interventions
Examine the impact of different treatment interventions on COVID-19 outcomes.
Developed by Our Team
-
COVID-19 Precision Medicine Analytics Platform Registry (JH-CROWN)
Johns Hopkins has created the JH-CROWN registry to gather information on all of the patients who have been seen at our health system with suspected or confirmed COVID-19. It will be used to learn about the pathobiology of COVID-19 and to better understand patient outcomes.
-
The COVID Inpatient Risk Calculator
The COVID Inpatient Risk Calculator uses factors on admission to the hospital to predict the likelihood that a patient admitted with COVID-19 will progress to severe disease or death within 7 days of arrival.
-
Severe COVID-19 Adaptive Risk Predictor (SCARP)
The COVID-19 adaptive risk predictor (SCARP) is a tool that calculates the 1-day and 7-day risk of progression to severe disease or death for adult patients (18 years and older) who are hospitalized with COVID-19.
Key Articles
- Aging in COVID-19: Vulnerability, immunity and intervention
- IgM autoantibodies recognizing ACE2 are associated with severe COVID-19
- Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination
- Operational recommendations for scarce resource allocation in a public health crisis
- Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study
- The role of dedicated biocontainment patient care units in preparing for COVID-19 and other infectious disease outbreaks
- The Risk of Not Being Ready: A Novel Approach to Managing Constant Readiness of a High-Level Isolation Unit During Times of Inactivity
- Genomics in the era of COVID-19: ethical implications for clinical practice and public health
- Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System
- Tocilizumab for the treatment of COVID-19 among hospitalized patients: A matched retrospective cohort analysis
- Myocardial Injury in Severe COVID-19 Compared to Non-COVID Acute Respiratory Distress Syndrome
- Inpatient COVID‐19 Outcomes in Solid Organ Transplant Recipients Compared to Non‐Solid Organ Transplant Patients: A Retrospective Cohort
- Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19
- Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study
- Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19
- Diagnostic accuracy of lung ultrasound for SARS-CoV-2: a retrospective cohort study
- Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
- Peripheral Plasma Cells Associated with Mortality Benefit in Severe COVID-19: A Marker of Disease Resolution
- Sex and gender differences in COVID testing, hospital admission, presentation, and drivers of severe outcomes in the DC/Maryland region
- Genomics in Patient Care and Workforce Decisions in High-Level Isolation Units: A Survey of Healthcare Workers
Patient Care for COVID-19
The Johns Hopkins biocontainment unit is a state-of-the art-facility designed to care for patients affected by high-consequence infectious diseases such as COVID-19. The unit is a multidisciplinary collaboration of experts from across the Johns Hopkins Health System and around the world. Find out more about the biocontainment unit.
